EBV-positive diffuse large B-cell lymphoma of the elderly: A case series from Peru

American Journal of Hematology

Volumn 86, Issue 8, 2011, Pages 663-667

  Beltran, Brady E ^a   Castillo, Jorge J ^b   Morales, Domingo ^a   de Mendoza, Fernando Hurtado ^a   Quinones, Pilar ^a   Miranda, Roberto N ^c   Gallo, Aly ^d   Lopez Ilasaca, Marco ^e   Butera, James N ^f   Sotomayor, Eduardo M ^g  

^a HOSPITAL NACIONAL EDGARDO REBAGLIATI MARTINS   (Peru)

^b MIRIAM HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d Center for Molecular Diagnostics   (Peru)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f RHODE ISLAND HOSPITAL   (United States)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERFERON REGULATORY FACTOR 4; PREDNISONE; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE; VIRUS RNA;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; EPSTEIN BARR VIRUS; FEMALE; GROUPS BY AGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; LYMPHOCYTE COUNT; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PERU; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; TREATMENT RESPONSE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOCYTE COUNT; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; PERU; PREDNISONE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEX DISTRIBUTION; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 79960357077     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22078     Document Type: Article

References (31)

1. Swerdlow S, Campo E, Harris N, et al. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues, 4th ed. Lyon: IARC; 2008.
2. Armitage JO. The changing classification of non-Hodgkin's lymphomas. CA Cancer J Clin 1997; 47: 323-325.
3. Hecht JL, Aster JC. Molecular biology of Burkitt's lymphoma. J Clin Oncol 2000; 18: 3707-3721.
4. Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: Lessons learned from 112 published cases. Am J Hematol 2008; 83: 804-809.
5. Kanavaros P, Briere J, Emile JF, et al. Epstein-Barr virus in T and natural killer (NK) cell non-Hodgkin's lymphomas. Leukemia 1996; 10 (Suppl 2): s84-s87.
6. Anagnostopoulos I, Hummel M, Finn T, et al. Heterogeneous Epstein-Barr virus infection patterns in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type. Blood 1992; 80: 1804-1812.
7. Pallesen G, Hamilton-Dutoit SJ, Rowe M, et al. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 1991; 337: 320-322.
8. Barrionuevo C, Anderson VM, Zevallos-Giampietri E, et al. Hydroa-like cutaneous T-cell lymphoma: A clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morphol 2002; 10: 7-14.
9. Nakamura S, Jaffe E, Swerdlow S. EBV positive diffuse large B-cell of the elderly. In: Swerdlow S, Campo E, Harris NL, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008. pp 243-244.
10. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
11. Hengge UR, Ruzicka T, Tyring SK, et al. Update on Kaposi's sarcoma and other HHV8 associated diseases. II. Pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis 2002; 2: 344-352.
12. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
13. Oyama T, Yamamoto K, Asano N, et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: A study of 96 patients. Clin Cancer Res 2007; 13: 5124-5132.
14. Kuze T, Nakamura N, Hashimoto Y, et al. The characteristics of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma: Comparison between EBV(+) and EBV(-) cases in Japanese population. Jpn J Cancer Res 2000; 91: 1233-1240.
15. Park S, Lee J, Ko YH, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 2007; 110: 972-978.
16. Hoeller S, Tzankov A, Pileri SA, et al. Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations. Hum Pathol 2010; 41: 352-357.
17. Gibson SE, Hsi ED. Epstein-Barr virus-positive B-cell lymphoma of the elderly at a United States tertiary medical center: An uncommon aggressive lymphoma with a nongerminal center B-cell phenotype. Hum Pathol 2009; 40: 653-661.
18. Morales D, Beltran B, De Mendoza FH, et al. Epstein-Barr virus as a prognostic factor in de novo nodal diffuse large B-cell lymphoma. Leuk Lymphoma 2010; 51: 66-72.
19. Castillo JJ, Beltran BE, Miranda RN, et al. Epstein-barr virus-positive diffuse large B-cell lymphoma of the elderly: What we know so far. Oncologist 2011; 16: 87-96.
20. Fagnoni FF, Vescovini R, Passeri G, et al. Shortage of circulating naive CD8(+) T cells provides new insights on immunodeficiency in aging. Blood 2000; 95: 2860-2868.
21. Franceschi C, Capri M, Monti D, et al. Inflammaging and anti-inflammaging: A systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 2007; 128: 92-105.
22. Naylor K, Li G, Vallejo AN, et al. The influence of age on T cell generation and TCR diversity. J Immunol 2005; 174: 7446-7452.
23. Spaulding C, Guo W, Effros RB. Resistance to apoptosis in human CD8+ T cells that reach replicative senescence after multiple rounds of antigen-specific proliferation. Exp Gerontol 1999; 34: 633-644.
24. Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011; 29: 200-207.
25. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009; 15: 5494-5502.
26. Song MK, Chung JS, Seol YM, et al. Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy. Ann Oncol 2010; 21: 140-144.
27. Talaulikar D, Choudhury A, Shadbolt B, et al. Lymphocytopenia as a prognostic marker for diffuse large B cell lymphomas. Leuk Lymphoma 2008; 49: 959-964.
28. Mentzer SJ, Fingeroth J, Reilly JJ, et al. Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma. Blood Cells Mol Dis 1998; 24: 114-123.
29. Perrine SP, Hermine O, Small T, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 2007; 109: 2571-2578.
30. Zou P, Kawada J, Pesnicak L, et al. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells. J Virol 2007; 81: 10029-10036.
31. Katano H, Pesnicak L, Cohen JI. Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Proc Natl Acad Sci USA 2004; 101: 4960-4965.